RESMED INC (RMD)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
RMD - RESMED INC
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.18
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.18
ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$28.88
18 Mar |
-0.270 OPEN $29.01 |
-0.93% HIGH $29.07 |
1,114,975 LOW $28.67 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY24 Forecast |
FY25 Forecast |
---|---|---|
EPS (cps) | 115.5 | xxx |
DPS (cps) | 29.9 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 25.3 | xxx |
Dividend Yield | 1.0% | xxx |
Div Pay Ratio(%) | 25.9% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 07/02 - ex-div 5.11c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 90.9 |
DPS All | xxx | xxx | xxx | xxx | xxx | 21.9 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 6,278.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 421.9 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 1,030.7 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 21.25 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 24.06 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 18.15 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 15.20 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 24.06 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 23.14 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 468.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 48 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2,326 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 2,373 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 4,162 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 342 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 7.78 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 199.2 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 3.17 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 2,839 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 1,727 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 428 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 221 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
RMD STOCK CHART
FNArena News on RMD
1 |
Uptrend Resumed For ResMed10:30 AM - Technicals |
2 |
Rudi’s View: CBA, GQG, Pilbara Minerals, Sonic Healthcare, Webjet & XeroMar 14 2024 - Rudi's View |
3 |
Rudi’s View: Healthcare Under The ScannerMar 13 2024 - Rudi's View |
4 |
Rudi’s View: Investing Is About The FutureMar 06 2024 - Rudi's View |
5 |
Rudi’s View: Week 3 – Not As Good, But Not BadFeb 28 2024 - Rudi's View |
Latest Medical Equipment & Devices News
1 |
Uptrend Resumed For ResMed10:30 AM - Technicals |
2 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
3 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
4 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
5 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
6 |
ResMed Makes A ComebackJan 29 2024 - Australia |
7 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |
8 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
9 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |